uPAR-targeting in vivo CAR-T (Peking University)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameuPAR-targeting in vivo CAR-T (Peking University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionUrokinase plasminogen activator surface receptor inhibitors
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsLiver CirrhosisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPeking UniversityCircode Biomed
China Registration ClassN/A

Develop Information

Active CompaniesCircode BiomedPeking University
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A